Levima Advanced Materials injects 150m yuan into bio-materials subsidiary

Levima Advanced Materials Corporation (SZSE:003022) will inject 150 million yuan into its controlled subsidiary, Jiangxi Keyuan Biomaterials Co., Ltd., to bolster its strategic focus on bio-degradable materials. The capital injection, approved on December 5, 2025, will increase Keyuan Biomaterials' registered capital by 88.50 million yuan to 295 million yuan, with the remaining 61.50 million yuan going into capital reserves. This move, deemed a related-party transaction, aims to enhance Keyuan Biomaterials' liquidity and capital structure, facilitating the early operation of its polylactic acid project.

Additionally, the company concurrently approved a plan to manage up to 1 billion yuan of idle own funds for 2026. This cash management initiative, effective from January 1, 2026, to December 31, 2026, will involve investing in low-risk, highly liquid wealth management products. The goal is to optimize the use of idle funds, generate additional returns, and safeguard shareholder interests without impacting daily operations.